Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 7Phase NA 2Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1CNS 1

Conditions

Recurrence 1Neuroblastoma 1Multiple Myeloma 1Cytokine Release Syndrome 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Has results × Leukapheresis × Clear all
NCT03338972 2023-09-08

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Completed
28 enrolled 18 charts
Plasma cell

Multiple Myeloma

NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Cancer Research UK

Phase 1 Completed
17 enrolled 17 charts
CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡